NIV Versus HFO for Acute Exacerbations of Interstitial Lung Diseases (IRAPIDPhysio)

Evaluation of Physiological Effects of Noninvasive Mechanical Ventilation and High-flow Oxygen Therapy for Acute Exacerbations of Interstitial Lung Diseases

The objectives of this study are to compare the physiological consequences of high-flow oxygen therapy and noninvasive mechanical ventilation on ventilation, respiratory work and hemodynamics during acute respiratory failure in diffuse interstitial pneumonia.

Study Overview

• Status: Not yet recruiting
• Conditions: Interstitial Lung Disease; Acute Respiratory Failure
• Intervention / Treatment: Device: Noninvasive mechanical ventilation; Device: Nasal high-flow oxygen therapy; Device: Continuous positive airway pressure

• Study Type: Interventional
• Enrollment (Estimated): 18
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Elise ARTAUD-MACARI, MD; Phone Number: +33232885992; Email: elise.artaud-macari@chu-rouen.fr
• Study Contact Backup: Name: Maryline LEFORT; Phone Number: +33232885992; Email: mlefort@adir-hautenormandie.com

Study Locations

• France
  • Rouen, France, 76000
    • ADIR Association
    • Sub-Investigator: David DEBEAUMONT, MD
    • Sub-Investigator: Christophe GIRAULT, MD
    • Sub-Investigator: Antoine CUVELIER, MD, PHD
    • Contact: Elise ARTAUD-MACARI, MD; Phone Number: +33232885992; Email: elise.artaud-macari@chu-rouen.fr
    • Sub-Investigator: Pierre Alexandre ROGER, MD
    • Sub-Investigator: Gurvan LEBOUAR, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion criteria:

• Age > 18 yrs
• Hospitalization in intensive care unit
• Acute exacerbation of a previously/presently documented diffuse (fibrotic) interstitial lung disease
• Dyspnea majoration since at least 1 month
• Alveolar or ground-glass opacities on CT-scan that are superposed to interstitial lung disease and not explained by left heart failure or volume overload
• Hypoxemia requiring oxygen flows > 6 L/min

Exclusion criteria:

• Contraindication to noninvasive ventilation or high-flow oxygen therapy
• Immediate indication to endotracheal intubation or hemodynamic assistance
• Body mass index > 40
• Presence of a pacemaker or an implantable defibrillator
• Presence of cutaneous lesions where Pulmovista® belt should be placed
• Moribund patient
• Pregnant or breastfeeding women or women of childbearing age without an effective method of contraception
• Protected adult patient (tutorship or curatorship)
• Patient deprived of liberty by court or administrative decision
• No possibility to install nasogastric tube
• Endotracheal or tracheostomy tube requirement during the study
• Hemodynamic assistance requirement during the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: NIV + CPAP + HFO; The patient will be placed under noninvasive mechanical ventilation during 30 min, then continuous positive airway pressure during 30 min and then nasal high-flow oxygen during 30 min. Each period will be separated by a washout period of maximum 30 min under oxygen with a non-rebreathing mask.	Device: Noninvasive mechanical ventilation; Noninvasive mechanical ventilation is a respiratory technique which allows the administration of positive inspiratory and expiratory airway pressures in order to ventilate the lungs.; Device: Nasal high-flow oxygen therapy; Nasal high-flow is a respiratory technique which allows the administration of warmed and humidified air, associated with oxygen.; Device: Continuous positive airway pressure; Continuous positive airway pressure is a respiratory technique which allows to maintain a constant positive airway pressure during inspiration and expiration.
Experimental: NIV + HFO + CPAP; The patient will be placed under noninvasive mechanical ventilation during 30 min, then nasal high-flow oxygen during 30 min and then continuous positive airway pressure during 30 min. Each period will be separated by a washout period of maximum 30 min under oxygen with a non-rebreathing mask.	Device: Noninvasive mechanical ventilation; Noninvasive mechanical ventilation is a respiratory technique which allows the administration of positive inspiratory and expiratory airway pressures in order to ventilate the lungs.; Device: Nasal high-flow oxygen therapy; Nasal high-flow is a respiratory technique which allows the administration of warmed and humidified air, associated with oxygen.; Device: Continuous positive airway pressure; Continuous positive airway pressure is a respiratory technique which allows to maintain a constant positive airway pressure during inspiration and expiration.
Experimental: CPAP + NIV + HFO; The patient will be placed under continuous positive airway pressure during 30 min, then noninvasive mechanical ventilation during 30 min and then nasal high-flow oxygen during 30 min. Each period will be separated by a washout period of maximum 30 min under oxygen with a non-rebreathing mask.	Device: Noninvasive mechanical ventilation; Noninvasive mechanical ventilation is a respiratory technique which allows the administration of positive inspiratory and expiratory airway pressures in order to ventilate the lungs.; Device: Nasal high-flow oxygen therapy; Nasal high-flow is a respiratory technique which allows the administration of warmed and humidified air, associated with oxygen.; Device: Continuous positive airway pressure; Continuous positive airway pressure is a respiratory technique which allows to maintain a constant positive airway pressure during inspiration and expiration.
Experimental: CPAP + HFO + NIV; The patient will be placed under continuous positive airway pressure during 30 min, then nasal high-flow oxygen during 30 min and then noninvasive mechanical ventilation during 30 min. Each period will be separated by a washout period of maximum 30 min under oxygen with a non-rebreathing mask.	Device: Noninvasive mechanical ventilation; Noninvasive mechanical ventilation is a respiratory technique which allows the administration of positive inspiratory and expiratory airway pressures in order to ventilate the lungs.; Device: Nasal high-flow oxygen therapy; Nasal high-flow is a respiratory technique which allows the administration of warmed and humidified air, associated with oxygen.; Device: Continuous positive airway pressure; Continuous positive airway pressure is a respiratory technique which allows to maintain a constant positive airway pressure during inspiration and expiration.
Experimental: HFO + CPAP + NIV; The patient will be placed under nasal high-flow oxygen during 30 min, then continuous positive airway pressure during 30 min and then noninvasive mechanical ventilation during 30 min. Each period will be separated by a washout period of maximum 30 min under oxygen with a non-rebreathing mask.	Device: Noninvasive mechanical ventilation; Noninvasive mechanical ventilation is a respiratory technique which allows the administration of positive inspiratory and expiratory airway pressures in order to ventilate the lungs.; Device: Nasal high-flow oxygen therapy; Nasal high-flow is a respiratory technique which allows the administration of warmed and humidified air, associated with oxygen.; Device: Continuous positive airway pressure; Continuous positive airway pressure is a respiratory technique which allows to maintain a constant positive airway pressure during inspiration and expiration.
Experimental: HFO + NIV + CPAP; The patient will be placed under nasal high-flow oxygen during 30 min, then noninvasive mechanical ventilation during 30 min and then continuous positive airway pressure during 30 min. Each period will be separated by a washout period of maximum 30 min under oxygen with a non-rebreathing mask.	Device: Noninvasive mechanical ventilation; Noninvasive mechanical ventilation is a respiratory technique which allows the administration of positive inspiratory and expiratory airway pressures in order to ventilate the lungs.; Device: Nasal high-flow oxygen therapy; Nasal high-flow is a respiratory technique which allows the administration of warmed and humidified air, associated with oxygen.; Device: Continuous positive airway pressure; Continuous positive airway pressure is a respiratory technique which allows to maintain a constant positive airway pressure during inspiration and expiration.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pulmonary compliance	Comparison of global pulmonary compliance (Cglob) under noninvasive ventilation (NIV) and high-flow oxygen therapy (HFO) during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pulmonary compliance	Comparison of global pulmonary compliance (Cglob) under NIV and continuous positive airway pressure (CPAP) during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Pulmonary compliance	Comparison of global pulmonary compliance (Cglob) under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Pulmonary compliance	Comparison of global pulmonary compliance (Cglob) under HFO and face mask oxygen therapy (FM) during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Pulmonary compliance	Comparison of global pulmonary compliance (Cglob) under NIV and face mask oxygen therapy (FM) during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Pulmonary compliance	Comparison of global pulmonary compliance (Cglob) under CPAP and face mask oxygen therapy (FM) during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Tidal volume	Comparison of Tidal volume under CPAP and face mask oxygen therapy (FM) during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Tidal volume	Comparison of Tidal volume under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Tidal volume	Comparison of Tidal volume under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Tidal volume	Comparison of Tidal volume under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Tidal volume	Comparison of Tidal volume under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Tidal volume	Comparison of Tidal volume under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
end-expiratory lung volume	Comparison of end-expiratory lung volume under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
end-expiratory lung volume	Comparison of end-expiratory lung volume under NIV and HFO during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
end-expiratory lung volume	Comparison of end-expiratory lung volume under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
end-expiratory lung volume	Comparison of end-expiratory lung volume under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
end-expiratory lung volume	Comparison of end-expiratory lung volume under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
end-expiratory lung volume	Comparison of end-expiratory lung volume under FM and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transpulmonary pressure	Comparison of transpulmonary pressure under FM and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transpulmonary pressure	Comparison of transpulmonary pressure under FM and HFO during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transpulmonary pressure	Comparison of transpulmonary pressure under FM and NIV during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transpulmonary pressure	Comparison of transpulmonary pressure under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transpulmonary pressure	Comparison of transpulmonary pressure under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transpulmonary pressure	Comparison of transpulmonary pressure under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
driving pressure	Comparison of driving pressure under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
driving pressure	Comparison of driving pressure under NIV and HFO during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
driving pressure	Comparison of driving pressure under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
driving pressure	Comparison of driving pressure under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
driving pressure	Comparison of driving pressure under CPAP and HFO during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
driving pressure	Comparison of driving pressure under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Global inhomogeneity index	Comparison of Global inhomogeneity index under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Global inhomogeneity index	Comparison of Global inhomogeneity index under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Global inhomogeneity index	Comparison of Global inhomogeneity index under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Global inhomogeneity index	Comparison of Global inhomogeneity index under NIV and HFO during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Global inhomogeneity index	Comparison of Global inhomogeneity index under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Global inhomogeneity index	Comparison of Global inhomogeneity index under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
respiratory rate	Comparison of respiratory rate under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
respiratory rate	Comparison of respiratory rate under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
respiratory rate	Comparison of respiratory rate under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
respiratory rate	Comparison of respiratory rate under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
respiratory rate	Comparison of respiratory rate under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
respiratory rate	Comparison of respiratory rate under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
inspiratory time	Comparison of inspiratory time under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
inspiratory time	Comparison of inspiratory time under NIV and HFO during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
inspiratory time	Comparison of inspiratory time under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
inspiratory time	Comparison of inspiratory time under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
inspiratory time	Comparison of inspiratory time under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
inspiratory time	Comparison of inspiratory time under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
inspiratory time	Comparison of inspiratory time under CPAP and HFO during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
oesophagal pressure swings	Comparison of oesophagal pressure variations between inspiration and expiration under CPAP and HFO during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
oesophagal pressure swings	Comparison of oesophagal pressure variations between inspiration and expiration under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
oesophagal pressure swings	Comparison of oesophagal pressure variations between inspiration and expiration under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
oesophagal pressure swings	Comparison of oesophagal pressure variations between inspiration and expiration under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
oesophagal pressure swings	Comparison of oesophagal pressure variations between inspiration and expiration under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
oesophagal pressure swings	Comparison of oesophagal pressure variations between inspiration and expiration under NIV and HFO during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transdiaphragmatic pressure variations	Comparison of transdiaphragmatic pressure variations between inspiration and expiration under NIV and HFO during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transdiaphragmatic pressure variations	Comparison of transdiaphragmatic pressure variations between inspiration and expiration under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transdiaphragmatic pressure variations	Comparison of transdiaphragmatic pressure variations between inspiration and expiration under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transdiaphragmatic pressure variations	Comparison of transdiaphragmatic pressure variations between inspiration and expiration under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transdiaphragmatic pressure variations	Comparison of transdiaphragmatic pressure variations between inspiration and expiration under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transdiaphragmatic pressure variations	Comparison of transdiaphragmatic pressure variations between inspiration and expiration under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transdiaphragmatic pressure time products	Comparison of transdiaphragmatic pressure time products under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transdiaphragmatic pressure time products	Comparison of transdiaphragmatic pressure time products under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transdiaphragmatic pressure time products	Comparison of transdiaphragmatic pressure time products under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transdiaphragmatic pressure time products	Comparison of transdiaphragmatic pressure time products under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transdiaphragmatic pressure time products	Comparison of transdiaphragmatic pressure time products under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transdiaphragmatic pressure time products	Comparison of transdiaphragmatic pressure time products under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
oesophagal pressure time products	Comparison of oesophagal pressure time products under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
oesophagal pressure time products	Comparison of oesophagal pressure time products under NIV and HFO during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
oesophagal pressure time products	Comparison of oesophagal pressure time products under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
oesophagal pressure time products	Comparison of oesophagal pressure time products under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
oesophagal pressure time products	Comparison of oesophagal pressure time products under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
oesophagal pressure time products	Comparison of oesophagal pressure time products under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
ultrasound diaphragmatic strain.	Comparison of ultrasound diaphragmatic strain under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
diaphragmatic thickening fraction	Comparison of diaphragmatic thickening fraction under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
diaphragmatic thickening fraction	Comparison of diaphragmatic thickening fraction under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
diaphragmatic thickening fraction	Comparison of diaphragmatic thickening fraction under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
diaphragmatic thickening fraction	Comparison of diaphragmatic thickening fraction under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
diaphragmatic thickening fraction	Comparison of diaphragmatic thickening fraction under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
diaphragmatic thickening fraction	Comparison of diaphragmatic thickening fraction under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
peak inspiratory flow	Comparison of peak inspiratory flow under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
peak inspiratory flow	Comparison of peak inspiratory flow under NIV and HFO during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
peak inspiratory flow	Comparison of peak inspiratory flow under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
peak inspiratory flow	Comparison of peak inspiratory flow under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
peak inspiratory flow	Comparison of peak inspiratory flow under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
peak inspiratory flow	Comparison of peak inspiratory flow under FM and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
peak expiratory flow	Comparison of peak expiratory flow under FM and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
peak expiratory flow	Comparison of peak expiratory flow under FM and NIV during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
peak expiratory flow	Comparison of peak expiratory flow under FM and HFO during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
peak expiratory flow	Comparison of peak expiratory flow under CPAP and HFO during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
peak expiratory flow	Comparison of peak expiratory flow under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
peak expiratory flow	Comparison of peak expiratory flow under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Systolic arterial pressures	Comparison of Systolic arterial pressures under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Systolic arterial pressures	Comparison of Systolic arterial pressures under NIV and HFO during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Systolic arterial pressures	Comparison of Systolic arterial pressures under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Systolic arterial pressures	Comparison of Systolic arterial pressures under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Systolic arterial pressures	Comparison of Systolic arterial pressures under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Systolic arterial pressures	Comparison of Systolic arterial pressures under CPAP and HFO during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Diastolic arterial pressures	Comparison of Diastolic arterial pressures under CPAP and HFO during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Diastolic arterial pressures	Comparison of Diastolic arterial pressures under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Diastolic arterial pressures	Comparison of Diastolic arterial pressures under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Diastolic arterial pressures	Comparison of Diastolic arterial pressures under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Diastolic arterial pressures	Comparison of Diastolic arterial pressures under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Diastolic arterial pressures	Comparison of Diastolic arterial pressures under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Mean arterial pressure	Comparison of Mean arterial pressures under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Mean arterial pressure	Comparison of Mean arterial pressures under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Mean arterial pressure	Comparison of Mean arterial pressures under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Mean arterial pressure	Comparison of Mean arterial pressures under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Mean arterial pressure	Comparison of Mean arterial pressures under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Mean arterial pressure	Comparison of Mean arterial pressures under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
systolic pulmonary arterial pressure	Comparison of systolic pulmonary arterial pressure under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
systolic pulmonary arterial pressure	Comparison of systolic pulmonary arterial pressure under NIV and HFO during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
systolic pulmonary arterial pressure	Comparison of systolic pulmonary arterial pressure under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
systolic pulmonary arterial pressure	Comparison of systolic pulmonary arterial pressure under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
systolic pulmonary arterial pressure	Comparison of systolic pulmonary arterial pressure under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
systolic pulmonary arterial pressure	Comparison of systolic pulmonary arterial pressure under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
tricuspid annular plane systolic excursion	Comparison of tricuspid annular plane systolic excursion under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
tricuspid annular plane systolic excursion	Comparison of tricuspid annular plane systolic excursion under CPAP and HFO during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
tricuspid annular plane systolic excursion	Comparison of tricuspid annular plane systolic excursion under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
tricuspid annular plane systolic excursion	Comparison of tricuspid annular plane systolic excursion under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
tricuspid annular plane systolic excursion	Comparison of tricuspid annular plane systolic excursion under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
tricuspid annular plane systolic excursion	Comparison of tricuspid annular plane systolic excursion under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
right ventricular strain	Comparison of right ventricular strain under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
right ventricular strain	Comparison of right ventricular strain under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
right ventricular strain	Comparison of right ventricular strain under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
right ventricular strain	Comparison of right ventricular strain under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
right ventricular strain	Comparison of right ventricular strain under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
right ventricular strain	Comparison of right ventricular strain under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
left ventricular ejection fraction	Comparison of left ventricular ejection fraction under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
left ventricular ejection fraction	Comparison of left ventricular ejection fraction under CPAP and HFO during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
left ventricular ejection fraction	Comparison of left ventricular ejection fraction under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
left ventricular ejection fraction	Comparison of left ventricular ejection fraction under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
left ventricular ejection fraction	Comparison of left ventricular ejection fraction under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
left ventricular ejection fraction	Comparison of left ventricular ejection fraction under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
E/E' ratio	Comparison of E/E' ratio under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
E/E' ratio	Comparison of E/E' ratio under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
E/E' ratio	Comparison of E/E' ratio under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
E/E' ratio	Comparison of E/E' ratio under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
E/E' ratio	Comparison of E/E' ratio under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
E/E' ratio	Comparison of E/E' ratio under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
right auricular pressure	Comparison of right auricular pressure under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
right auricular pressure	Comparison of right auricular pressure under CPAP and HFO during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
right auricular pressure	Comparison of right auricular pressure under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
right auricular pressure	Comparison of right auricular pressure under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
right auricular pressure	Comparison of right auricular pressure under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
right auricular pressure	Comparison of right auricular pressure under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
cardiac output	Comparison of cardiac output under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
cardiac output	Comparison of cardiac output under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
cardiac output	Comparison of cardiac output under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
cardiac output	Comparison of cardiac output under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
cardiac output	Comparison of cardiac output under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
cardiac output	Comparison of cardiac output under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
heart rate	Comparison of heart rate under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
heart rate	Comparison of heart rate under CPAP and HFO during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
heart rate	Comparison of heart rate under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
heart rate	Comparison of heart rate under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
heart rate	Comparison of heart rate under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
heart rate	Comparison of heart rate under NIV and HFO during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Pulsed oxymetry	Comparison of pulsed oxymetry under NIV and HFO during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Pulsed oxymetry	Comparison of pulsed oxymetry under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Pulsed oxymetry	Comparison of pulsed oxymetry under NIV and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Pulsed oxymetry	Comparison of pulsed oxymetry under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Pulsed oxymetry	Comparison of pulsed oxymetry under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Pulsed oxymetry	Comparison of pulsed oxymetry under CPAP and HFO during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transcutaneous carbon dioxide pressure	Comparison of transcutaneous carbon dioxide pressure under CPAP and HFO during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transcutaneous carbon dioxide pressure	Comparison of transcutaneous carbon dioxide pressure under CPAP and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transcutaneous carbon dioxide pressure	Comparison of transcutaneous carbon dioxide pressure under CPAP and NIV during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transcutaneous carbon dioxide pressure	Comparison of transcutaneous carbon dioxide pressure under FM and NIV during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transcutaneous carbon dioxide pressure	Comparison of transcutaneous carbon dioxide pressure under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
transcutaneous carbon dioxide pressure	Comparison of transcutaneous carbon dioxide pressure under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Dyspnea	Comparison of Borg's scale (from 0 to 10, 10 is maximal dyspnea) under HFO and FM during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Dyspnea	Comparison of Borg's scale (from 0 to 10, 10 is maximal dyspnea) under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Dyspnea	Comparison of Borg's scale (from 0 to 10, 10 is maximal dyspnea) under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Dyspnea	Comparison of Borg's scale (from 0 to 10, 10 is maximal dyspnea) under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Dyspnea	Comparison of Borg's scale (from 0 to 10, 10 is maximal dyspnea) under FM and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Dyspnea	Comparison of Borg's scale (from 0 to 10, 10 is maximal dyspnea) under FM and NIV during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Comfort	Visual comfort scale (from 0 to 10, 10 is maximal confort) under FM and NIV during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Comfort	Visual comfort scale (from 0 to 10, 10 is maximal confort) under FM and HFO during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Comfort	Visual comfort scale (from 0 to 10, 10 is maximal confort) under FM and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Comfort	Visual comfort scale (from 0 to 10, 10 is maximal confort) under NIV and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Comfort	Visual comfort scale (from 0 to 10, 10 is maximal confort) under HFO and CPAP during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device
Comparison of Comfort	Visual comfort scale (from 0 to 10, 10 is maximal confort) under HFO and NIV during acute respiratory failure in diffuse interstitial pneumonia.	During the intervention, after an exposure of 30 minutes to the oxygen therapy device

Collaborators and Investigators

• Sponsor: ADIR Association
• Investigators: Principal Investigator: Elise ARTAUD-MACARI, MD, Rouen University Hospital

Study record dates

Study Major Dates

• Study Start (Estimated): January 1, 2024
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2026

Study Registration Dates

• First Submitted: August 22, 2023
• First Submitted That Met QC Criteria: December 13, 2023
• First Posted (Estimated): December 27, 2023

Study Record Updates

• Last Update Posted (Estimated): December 27, 2023
• Last Update Submitted That Met QC Criteria: December 13, 2023
• Last Verified: December 1, 2023

More Information

Terms related to this study

• Keywords: Diaphragm; Hemodynamics; Noninvasive mechanical ventilation; Nasal high-flow oxygen therapy; Respiratory work
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Respiration Disorders; Lung Diseases; Respiratory Insufficiency; Lung Diseases, Interstitial
• Other Study ID Numbers: IRAPIDPhysio

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No